Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/8/13 → 10/31/16 |
Funding
- Astellas Pharma Global Development Incorporated: $21,655.00
A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de novo Kidney Transplant Recipients
- Shah, Malay (PI)